Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sutro BiopharmaSTRO -4.16%45 3-Year EBITDA Growth Rate is 7.70% as of Jun. 2026, which is 148% above its 10-year median of 3.10. GuruFocus rates STRO with a GF Score™ of 45/100 and a GF Value™ of $5.50 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,131 Biotechnology companies, Sutro Biopharma ranks worse than 58.71% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 7.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -11.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sutro Biopharma was 28.60% per year. The lowest was -9.80% per year. And the median was 3.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Sutro Biopharma 3-Year EBITDA Growth Rate Related Terms
STRO vs AVIR, IPSC, CCCC: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Sutro Biopharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sutro Biopharma 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 7.70% mean?
Sutro Biopharma (STRO) has a 3-Year EBITDA Growth Rate of 7.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sutro Biopharma and its competitors. This is 148% above median its historical median of 3.10. According to the industry distribution chart, Sutro Biopharma ranks #664 out of 1131 companies in the Biotechnology industry, placing it in the top 58.7%.
Is Sutro Biopharma's 3-Year EBITDA Growth Rate too high?
Sutro Biopharma's current 3-Year EBITDA Growth Rate of 7.70% is 148% above median its 10-year median of 3.10. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Sutro Biopharma's value of 7.70% is 48.3% below this industry median. Based on the distribution chart, Sutro Biopharma ranks #664 out of 1131 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sutro Biopharma has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's 3-Year EBITDA Growth Rate compare to AVIR and IPSC?
According to the Biotechnology industry distribution chart, Sutro Biopharma ranks #664 out of 1131 companies for 3-Year EBITDA Growth Rate. This places Sutro Biopharma in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Sutro Biopharma's value of 7.70% is 48.3% below this benchmark. While the company's 10-year median is 3.10 vs. the industry median of 14.90, Sutro Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sutro Biopharma's current 3-Year EBITDA Growth Rate of 7.70% is 48.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sutro Biopharma and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sutro Biopharma's current 3-Year EBITDA Growth Rate is 7.70%, which is 148% above median its own 10-year median of 3.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sutro Biopharma (STRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.50, compared to a current price of $20.46 — trading 272% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 7.70%, which is 148% above median its 10-year median of 3.10 and 48.3% below the Biotechnology industry median of 14.90. Sutro Biopharma's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Sutro Biopharma (STRO), the current 3-Year EBITDA Growth Rate is 7.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sutro Biopharma (STRO) Overvalued in 2026?
Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued.
The current stock price of $20.46 is trading 272% above its estimated GF Value™ of $5.50.
GuruFocus considers Sutro Biopharma to be Significantly Overvalued.
Key valuation signals for STRO:
3-Year EBITDA Growth Rate: 7.70% (148% above median its 10-year median of 3.10)
GF Value™: $5.50 vs. price of $20.46 (272% above fair value)
Industry Position: 48.3% below the Biotechnology median (#664 of 1131)
No single metric tells the full story. See the STRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
45GF Score
Get the complete analysis for STRO
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STRO has been successfully added to your 
